Clinical Trials Logo

Nonalcoholic Fatty Liver Disease clinical trials

View clinical trials related to Nonalcoholic Fatty Liver Disease.

Filter by:

NCT ID: NCT03683589 Completed - Clinical trials for Bariatric Surgery Candidate

De Novo Lipogenesis in Severity of NAFLD

Start date: February 1, 2019
Phase:
Study type: Observational

NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.

NCT ID: NCT03674476 Completed - NAFLD Clinical Trials

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Start date: September 11, 2018
Phase: Phase 1
Study type: Interventional

This is an investigational study to evaluate the experimental medication BMS-986036 in participants with different levels of kidney function.

NCT ID: NCT03656744 Completed - NAFLD Clinical Trials

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

NCT ID: NCT03566173 Completed - Acute Pancreatitis Clinical Trials

Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis

Start date: March 10, 2018
Phase:
Study type: Observational [Patient Registry]

The early evaluation of AP severity are vital. Previous studies have shown non-alcoholic fatty liver disease (NAFLD) is associated with severity of acute pancreatitis (AP). This study is aimed to investigate the relationship between NAFLD and AP severity.

NCT ID: NCT03461562 Completed - Clinical trials for Nonalcoholic Fatty Liver Disease

Effectiveness of Exercise Applications on Hepatic Steatosis and Physical Fitness in Patients With NAFLD

Start date: January 5, 2018
Phase: N/A
Study type: Interventional

Purpose of the study will investigate the effects of two different training programs on hepatic steatosis and physical fitness parameters. This trial is designed in a randomized controlled study plan and aerobic training (40 minutes) wil be combined with Whole Body Vibration Training (WBVT for 15 minutes) which is made up of a shorter time application. WBVT to be applied instead of the resistance exercises.

NCT ID: NCT03445208 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Start date: February 14, 2018
Phase: Phase 1
Study type: Interventional

This is a study of experimental medication BMS-986036 given to healthy participants.

NCT ID: NCT03434613 Completed - Dyslipidemias Clinical Trials

Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease

Start date: May 14, 2018
Phase: Phase 4
Study type: Interventional

To investigate the therapeutic effect of ezetimibe on nonalcoholic fatty liver disease, the effect of rosuvastatin 5mg monotherapy and rosuvastatin 5mg / ezetimibe 10mg combination therapy n patients with hyperlipidemia and fatty liver will be compared and analyzed. This study included a total of 70 patients (35 per subgroup) for randomized controlled trials with prospective, open label, randomized, single-institution clinical trials. The drug will be maintained for a total of six months. The primary endpoint is the difference of liver fat change measured by MRI-PDFF in colocalized regions of interest within nine liver segments between two groups.

NCT ID: NCT03386890 Recruiting - Liver Fibrosis Clinical Trials

Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis

Start date: December 2015
Phase: N/A
Study type: Observational

Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China. As NAFLD can progress to Non-alcoholic steatohepatitis (NASH), cirrhosis and Hepatocarcinoma, the identification and quantitative evaluation of liver steatosis and its dynamic changes are crucial. While liver biopsy is still the gold standard in the diagnosis of NAFLD, its application is limited because of the invasive procedure.The Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) is a new non-invasive diagnostic method for fatty liver and liver fibrosis. In order to evaluate the diagnostic value of non-invasive assessment for the degree of liver steatosis and staging liver fibrosis, this non-invasive method will be assessed by the golden standard of liver biopsy among 400 NAFLD patients.The treatment protocols will be decided by doctor and patient both (treatment protocols and medicine are not required). Blood routine, blood biochemistry, abdominal ultrasound and Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) are detected during the follow-up.

NCT ID: NCT03375580 Recruiting - Clinical trials for Nonalcoholic Fatty Liver Disease

Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD

Start date: December 31, 2017
Phase: N/A
Study type: Interventional

This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement in NAFLD parameters and changes in intestinal functions.

NCT ID: NCT03366987 Completed - Atrial Fibrillation Clinical Trials

Nonalcoholic Fatty Liver Disease is Associated With Increased Atrial Fibrillation Risk in an Elderly Chinese Population

Start date: December 12, 2017
Phase:
Study type: Observational

Atrial fibrillation and nonalcoholic fatty liver disease are two pathological conditions that are highly prevalent worldwide and share multiple CVD risk factors. There is rare research performed among elderly adults. The investigators are conducting a cross-sectional analysis of elderly adults (≥65 years) to investigate the association between atrial fibrillation and nonalcoholic fatty liver disease in an elderly Chinese population.